MetLife Investment Management LLC Raises Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

MetLife Investment Management LLC boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 8.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,486 shares of the company's stock after acquiring an additional 1,190 shares during the period. MetLife Investment Management LLC's holdings in Medpace were worth $5,145,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. R Squared Ltd purchased a new stake in Medpace during the 4th quarter valued at about $30,000. SBI Securities Co. Ltd. purchased a new stake in Medpace in the fourth quarter valued at approximately $31,000. Jones Financial Companies Lllp increased its holdings in Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after buying an additional 110 shares during the period. Lindbrook Capital LLC raised its position in Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after buying an additional 29 shares during the last quarter. Finally, Assetmark Inc. lifted its stake in Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after acquiring an additional 29 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Trading Down 1.4 %

MEDP traded down $4.33 on Friday, hitting $298.55. 399,606 shares of the company's stock were exchanged, compared to its average volume of 339,939. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $459.77. The stock has a market cap of $9.02 billion, a price-to-earnings ratio of 23.64, a P/E/G ratio of 3.81 and a beta of 1.46. The firm has a 50-day moving average price of $313.79 and a 200-day moving average price of $331.76.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $3.06 by $0.61. The firm had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same quarter last year, the firm earned $3.20 earnings per share. On average, equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on MEDP. TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and lowered their price target for the company from $370.00 to $328.00 in a report on Monday, April 14th. Robert W. Baird lowered their target price on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday. William Blair reiterated a "market perform" rating on shares of Medpace in a research report on Tuesday. Leerink Partners began coverage on Medpace in a research report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective on the stock. Finally, Truist Financial decreased their target price on shares of Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a research note on Wednesday. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $349.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.